← Back to Clinical Trials
Recruiting NCT06044649

NCT06044649 Moderators and Mediators (M & M Trial) of Psychosocial Treatments of Chronic Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06044649
Status Recruiting
Phase
Sponsor Rush University Medical Center
Condition Chronic Pain
Study Type INTERVENTIONAL
Enrollment 460 participants
Start Date 2023-11-15
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Cognitive Behavioral TherapyAcceptance and Commitment TherapyEmotional Awareness and Expression Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 460 participants in total. It began in 2023-11-15 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic musculoskeletal pain (CP) is a major public health concern. Psychosocial treatments have been shown to be efficacious when compared to largely inert control conditions, but they are characterized by modest effects on primary outcomes. One strategy to boost efficacy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. Another strategy is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, the authors will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators, 460 participants will be randomized to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. The researchers will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. The goal of the study is to identify the most powerful treatment mechanisms - specific and shared -- and reveal for whom the mediator-outcome pathways are strongest.This project can increase the effects of our psychosocial chronic pain treatments by identifying the most effective treatment mechanisms and by informing patient-treatment matches that can optimize treatment effects.

Eligibility Criteria

Inclusion Criteria: * Back/neck is primary pain location (e.g., back/neck pain greater than leg pain) * Pain for at least 3 months and experienced 4 or more days/week for the past 6 months * Pain intensity last week is \>= 3 (0 to 10 rating scale) * Pain interference last week is \>= 3 (0 to 10 rating scale) * At least age 18 * Lives in United States * Fluent in English * Has personal computer/tablet and internet access * Able to attend weekly sessions * Willing to be randomized * Seeking to improve their pain-related status via a psychological therapy Exclusion Criteria: Past 2 years (treated for or having experienced): * Complex regional pain syndrome * Epilepsy/seizure disorder * Autoimmune disease * Liver disease * Cancer * Heart disease * Substance dependence or use disorder * Schizophrenia or other psychotic disorder * Bipolar disorder * Obsessive-compulsive disorder * Borderline personality disorder * Suicide attempt or suicide intention or impulse Also: * Major medical procedure scheduled within next 9 months * Applied for/ litigating for pain-related disability/worker's compensation (past year). * Major life event/stressor in past 6 months * Cognitive impairment (screener score \<=4)

Contact & Investigator

Central Contact

John W Burns, PhD

✉ john_burns@rush.edu

📞 312-942-0379

Principal Investigator

John W Burns, PhD

PRINCIPAL INVESTIGATOR

Rush University Medical Center

Frequently Asked Questions

Who can join the NCT06044649 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06044649 currently recruiting?

Yes, NCT06044649 is actively recruiting participants. Contact the research team at john_burns@rush.edu for enrollment information.

Where is the NCT06044649 trial being conducted?

This trial is being conducted at Chicago, United States, Detroit, United States.

Who is sponsoring the NCT06044649 clinical trial?

NCT06044649 is sponsored by Rush University Medical Center. The principal investigator is John W Burns, PhD at Rush University Medical Center. The trial plans to enroll 460 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology